Physician profile
Darshana Alle
NPI 1346458106
$3,138.66
in general payments reported to CMS, 2019-2025
21 companies · $381 in 2025
The $381 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $340 · 2020: $347 · 2021: $221 · 2022: $160 · 2023: $977 · 2024: $712 · 2025: $381.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,064 · Education: $6.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,063.78 |
| Education | $6.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $792.07 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $616.81 | 2019-2024 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $424.69 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Genzyme Corporation | $272.47 | 2019-2024 | |
| Csl Behring | $215.22 | 2019-2023 | Haegarda |
| Novartis Pharmaceuticals Corporation | $124.35 | 2021-2024 | |
| Novo Nordisk INC | $124.00 | 2025 | Wegovy |
| Kaleo, INC. | $120.13 | 2020-2024 | Auvi-Q |
| Takeda Pharmaceuticals U.S.A., INC. | $66.37 | 2021-2023 | Takhzyro |
| Amgen INC. | $53.87 | 2023-2024 | Tezspire |
| Pfizer INC. | $51.75 | 2020-2023 | |
| Aimmune Therapeutics, INC. | $45.24 | 2021-2022 | |
| Incyte Corporation | $41.57 | 2022 | |
| Grifols USA, LLC | $40.76 | 2023-2024 | Xembify |
| Blueprint Medicines Corporation | $31.28 | 2023-2024 | Ayvakit |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phadia US INC. | $23.21 | 2023 | Immunocap |
| Genentech USA, INC. | $23.01 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $20.69 | 2020 | |
| Biocryst US Sales Co., LLC | $18.93 | 2024 | Orladeyo |
| Pharming Healthcare, INC. | $18.42 | 2021 | |
| Aytu Biopharma, INC. | $13.82 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darshana Alle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.